---
document_datetime: 2024-10-18 10:02:13
document_pages: 19
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/imraldi-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: imraldi-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 11.6889113
conversion_datetime: 2025-12-21 23:20:47.898432
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Imraldi

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0074              | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 26/09/2024                          |                                             | SmPC and PL                      |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| N/0073    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                      | 08/08/2024   |            | PL          |          |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|----------|
| IB/0072   | B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation                                                                                                                                                                                                                                                                                                                             | 02/07/2024   | n/a        |             |          |
| IA/0071/G | This was an application for a group of variations. B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change approved stability protocol                                                                                    | 27/03/2024   | n/a        |             | to an    |
| IB/0070   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                        | 23/01/2024   | 16/02/2024 | SmPC and PL |          |
| IA/0069   | B.II.f.1.e - Stability of FP - Change to an approved stability protocol                                                                                                                                                                                                                                                                                                                                               | 29/11/2023   | n/a        |             |          |
| II/0066/G | This was an application for a group of variations. B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method B.I.a.1.j - Change in the manufacturer of AS or of a material/reagent/intermediate for AS - | 19/10/2023   | n/a        |             | starting |

<div style=\"page-break-after: always\"></div>

|                     | Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method                                                                                                                                                                                                                                                                                                                                                  |            |     |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| IAIN/0068/G         | This was an application for a group of variations. B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) | 09/10/2023 | n/a |                                   |
| PSUSA/10783 /202212 | Periodic Safety Update EU Single assessment - adalimumab                                                                                                                                                                                                                                                                                                                                                                                                                                   | 31/08/2023 | n/a | PRAC Recommendation - maintenance |
| IB/0067/G           | This was an application for a group of variations. B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the dossier) - Deletion of a supplier                                                                        | 26/07/2023 | n/a |                                   |
| IB/0064             | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other                                                                                                                                                                                                                                                                                                                                                                                              | 28/04/2023 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

|           | to a test procedure (including replacement addition) for the AS or a starting                                                                                                                                                                                                               |            |            |                 | changes or material/intermediate   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|------------------------------------|
| IB/0063   | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                      | 31/03/2023 | n/a        |                 |                                    |
| IB/0062/G | This was an application for a group of variations. B.II.f.1.e - Stability of FP - Change to an approved stability protocol B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved | 24/03/2023 | 16/02/2024 | SmPC            | stability protocol                 |
| IA/0061   | B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol                                                                                                                                                  | 08/12/2022 | n/a        |                 |                                    |
| IA/0060/G | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites                                                                                                              | 31/10/2022 | 31/03/2023 | Annex II and PL |                                    |
| IB/0058   | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                            | 18/10/2022 | n/a        |                 |                                    |

<div style=\"page-break-after: always\"></div>

| IB/0059   | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                            | 12/10/2022   | n/a        |      |           |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------|-----------|
| IB/0056   | B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation                                                                                                                                                         | 08/08/2022   | n/a        |      |           |
| IB/0055   | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                            | 08/08/2022   | n/a        |      |           |
| IB/0054   | B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol                                                               | 08/08/2022   | 31/03/2023 | SmPC |           |
| IA/0057   | B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol                                                                                                        | 05/08/2022   | n/a        |      |           |
| IB/0051   | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                                                        | 06/07/2022   | n/a        |      |           |
|           | This was an application for a group of variations. B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol B.I.d.1.c - Stability of AS - Change in the re-test | 09/06/2022   | n/a        |      | IA/0053/G |

<div style=\"page-break-after: always\"></div>

|           | period/storage period or storage conditions - Change to an approved stability protocol                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |            |            |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0052   | B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 24/05/2022 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| R/0050    | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 24/02/2022 | 29/04/2022 | SmPC and PL            | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Imraldi in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| II/0048/G | This was an application for a group of variations. B.II.a.5 - Change in concentration of a single-dose, total use parenteral product, where the amount of AS per unit dose (i.e. the strength) remains the same B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.a.3.b.3 - Changes in the composition (excipients) of the finished product - Other excipients - Change that relates to a biological/immunological product | 07/04/2022 | 31/03/2023 | SmPC, Labelling and PL | The SmPC, labelling and package leaflet have been updated to reflect the introduction of an additional concentration of 40 mg/0.4 mL (same 40 mg strength) for the solution for subcutaneous injection in pre-filled syringe and pre-filled pen as additional presentations, the change in excipients composition and shelf life and storage conditions for the finished product (12 months when stored at 5 ± 3°C and up to 31 days at 25°C): The additional presentations are packs of: - 1 pre-filled syringe, with 2 alcohol pads (EU/1/17/1216/010) - 2 pre-filled syringes, each with 1 alcohol pad (EU/1/17/1216/011) - 4 pre-filled syringes, each with 1 alcohol pad (EU/1/17/1216/012) - 6 pre-filled syringes, each with 1 alcohol pad (EU/1/17/1216/013) - 1 pre-filled pen, with 2 alcohol pads (EU/1/17/1216/014) |

<div style=\"page-break-after: always\"></div>

|           | B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes                                               |            |            |                       | - 2 pre-filled pens, each with 1 alcohol pad (EU/1/17/1216/015) - 4 pre-filled pens, each with 1 alcohol pad (EU/1/17/1216/016) - 6 pre-filled pens, each with 1 alcohol pad (EU/1/17/1216/017)   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0049   | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                                                                                                                                    | 22/11/2021 | n/a        |                       |                                                                                                                                                                                                   |
| IB/0047   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                        | 21/06/2021 | 09/07/2021 | SmPC and PL           |                                                                                                                                                                                                   |
| IB/0046/G | This was an application for a group of variations. B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate | 04/05/2021 | 09/07/2021 | SmPC, Annex II and PL |                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

|           | change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release   |            |            |                 | A.4 - Administrative   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|------------------------|
| IA/0045/G | This was an application for a group of variations. B.II.f.1.e - Stability of FP - Change to an approved stability protocol B.II.f.1.e - Stability of FP - Change to an approved stability protocol                                                                                                                                                                                                                                                                                                                                                    | 19/04/2021 | n/a        |                 |                        |
| IAIN/0044 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 29/03/2021 | 09/07/2021 | SmPC and PL     |                        |
| IAIN/0043 | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                                                                                                                                                                                | 26/03/2021 | 09/07/2021 | Annex II and PL |                        |
| IA/0042   | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 15/01/2021 | n/a        |                 | procedure              |

<div style=\"page-break-after: always\"></div>

| IB/0041   | B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 22/12/2020   | n/a        |                       |                                              |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------------|----------------------------------------------|
| II/0037/G | This was an application for a group of variations. B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or the manufacture of the AS or | 29/10/2020   | 22/01/2021 | Annex II              | intermediate used in manufacturer of a novel |
| IB/0040/G | This was an application for a group of variations. B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference Implementation of change(s) for which NO                                                                                                                                                      | 14/10/2020   | 22/01/2021 | SmPC, Annex II and PL | product -                                    |

<div style=\"page-break-after: always\"></div>

|                     | new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH   |            |            |             |                                   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------|
| IAIN/0039           | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                            | 09/10/2020 | 22/01/2021 | SmPC and PL |                                   |
| PSUSA/10783 /201912 | Periodic Safety Update EU Single assessment - adalimumab                                                                                                                                                                                                                                                                  | 03/09/2020 | n/a        |             | PRAC Recommendation - maintenance |
| IB/0038             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                             | 29/07/2020 | n/a        |             |                                   |
| IB/0035             | B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation                                                                                                                                                                                                                                              | 27/04/2020 | n/a        |             |                                   |
| IB/0033             | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                                                                                                                                | 20/03/2020 | n/a        |             |                                   |
| IB/0034             | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                                    | 29/01/2020 | n/a        |             |                                   |
| IB/0032             | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following                                                                                                                                                                                                                            | 18/01/2020 | 22/01/2021 | SmPC        |                                   |

<div style=\"page-break-after: always\"></div>

|          | assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                |            |            |                        |
|----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|
| IB/0031  | B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation                                                                                                                                 | 13/01/2020 | n/a        |                        |
| IB/0030  | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate | 27/11/2019 | n/a        |                        |
| IB/0029  | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                | 26/09/2019 | n/a        |                        |
| IB/0028  | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate | 11/09/2019 | n/a        |                        |
| X/0019/G | This was an application for a group of variations. Annex I_2.(c) Change or addition of a new strength/potency C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation | 27/06/2019 | 26/08/2019 | SmPC, Labelling and PL |

<div style=\"page-break-after: always\"></div>

| PSUSA/10589 /201812   | Periodic Safety Update EU Single assessment - adalimumab (biosimilars)                                                                                                                                                                                       | 11/07/2019   | n/a        |                   | PRAC Recommendation - maintenance   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------------|-------------------------------------|
| IB/0027               | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                       | 25/06/2019   | n/a        |                   |                                     |
| IA/0026               | B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol                                                                                                                   | 06/05/2019   | n/a        |                   |                                     |
| IB/0023               | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 17/04/2019   | 26/08/2019 | SmPC and Annex II |                                     |
| IB/0022               | B.II.f.1.d - Stability of FP - Change in storage conditions of the finished product or the diluted/reconstituted product                                                                                                                                     | 15/03/2019   | 26/08/2019 | SmPC and PL       |                                     |
| II/0021               | B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol   | 14/03/2019   | n/a        |                   |                                     |
| IA/0024/G             | This was an application for a group of variations. A.5.b - Administrative change - Change in the name                                                                                                                                                        | 21/02/2019   | n/a        |                   |                                     |

<div style=\"page-break-after: always\"></div>

|           | of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) B.II.b.5.a - Change to in-process tests or limits applied during the manufacture of the finished product - Tightening of in-process limits B.II.b.5.a - Change to in-process tests or limits applied during the manufacture of the finished product - Tightening of in-process limits   |            |            |                        | and/or address   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------|
| IB/0020   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                           | 24/01/2019 | 12/02/2019 | SmPC and PL            |                  |
|           | B.I.d.1.b.3 - Stability of AS - Change in the storage conditions - Change in storage conditions of the AS                                                                                                                                                                                                                                                                                                              | 18/01/2019 | n/a        |                        | IB/0018          |
| T/0015    | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                    | 02/10/2018 | 29/10/2018 | SmPC, Labelling and PL |                  |
| IB/0017/G | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by MAH                                                                                                            | 11/10/2018 | 12/02/2019 | SmPC and PL            | the              |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|             | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |            |            |                        |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|
| IB/0014/G   | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 20/08/2018 | 28/09/2018 | SmPC and PL            |
| IAIN/0013/G | This was an application for a group of variations. B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 12/07/2018 | 28/09/2018 | SmPC, Labelling and PL |

<div style=\"page-break-after: always\"></div>

|                     | tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes   |            |            |          |                                                                                                                                                          |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|----------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10589 /201712 | Periodic Safety Update EU Single assessment - adalimumab (biosimilars)                                                                                                                                                                                                                                                                                                                                                                                                                                    | 12/07/2018 | n/a        |          | PRAC Recommendation - maintenance                                                                                                                        |
| IAIN/0012/G         | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                               | 06/06/2018 | n/a        |          |                                                                                                                                                          |
| II/0005/G           | This was an application for a group of variations. B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a                                                                                                                                                                                                                                                     | 25/05/2018 | 28/09/2018 | Annex II | Annex II.A has been updated as follows: Name and address of the manufacturer(s) of the biological active substance(s) Biogen (Denmark) Manufacturing ApS |

<div style=\"page-break-after: always\"></div>

|           | biological/immunological product B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method                                                                                               |            |            |                        | Biogen Allé 1 3400 Hillerød Denmark   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|---------------------------------------|
| IB/0010   | B.IV.1.a.1 - Change of a measuring or administration device - Addition or replacement of a device which is not an integrated part of the primary packaging - Device with CE marking                                                                                                                                                                                                                                                                                                                                                                                                                                          | 24/05/2018 | 28/09/2018 | SmPC, Labelling and PL |                                       |
| II/0007/G | This was an application for a group of variations. B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method | 26/04/2018 | n/a        |                        |                                       |

<div style=\"page-break-after: always\"></div>

| IB/0009/G   | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 23/04/2018   | n/a        |                                  |                                                                                                                                                                        |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0004     | arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place Submission of an updated RMP version 2.1 in order to indicate changes in the distribution method for the Imraldi Patient Alert Card (PAC)from being included in the Annex IIIA of the Product Information to be provided to patients by healthcare professionals by including the PAC in the physician educational material. The Annexes I, II, IIIA and IIIB of the PI are updated accordingly. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated | 12/04/2018   | 28/09/2018 | SmPC, Annex II, Labelling and PL | The product information has been updated to change the Patient Alert Card (PAC) distribution; PAC will be given by the HCP and not included in the commercial package. |
| II/0002/G   | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 08/02/2018   | 28/09/2018 | SmPC, Annex II, Labelling and PL | The Product information has been updated to introduce the new 40mg solution for injection in prefilled pen presentations.                                              |

<div style=\"page-break-after: always\"></div>

|           | B.II.b.1.d - Replacement or addition of a manufacturing site for the FP - Site which requires an initial or product specific inspection B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.II.e.1.b.2 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Sterile medicinal products and biological/immunological medicinal products B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g.   |            |            |             |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|
| IB/0006/G | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 23/01/2018 | 28/09/2018 | SmPC and PL |

<div style=\"page-break-after: always\"></div>

|         | generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH   |            |     |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IA/0003 | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                                                                                                              | 15/12/2017 | n/a |
| IA/0001 | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                                                                                                                                                          | 12/09/2017 | n/a |